London, Ontario, Canada, January 10, 2011 / b3c newswire / - Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT) announced today that representatives of the Company will meet with several prospective partners who have expressed interest in its lead oncology drug candidate COTI-2 at Biotech Showcase. Biotech Showcase is a pharmaceutical partnering conference held concurrent to J.P. Morgan's 29th annual Healthcare Conference taking place in San Francisco, California on January 10-12, 2011.
The objective of these meetings is to present compelling data on COTI’s potentially first-in-class and best-in-class oncology compound, COTI-2, and to further discussions surrounding a licensing deal. During preclinical testing, COTI-2 has demonstrated greater selectivity, an improved safety profile and superior pharmacokinetics in comparison to other Akt inhibitors.
COTI will meet with several prospective partners including executives from major pharmaceutical organizations at Biotech Showcase. “We are delighted with the continued development of our lead oncology candidate, COTI-2,” said Dr. Wayne Danter, Chief Executive Officer (CEO) of COTI. “The results generated to date combined with the novel target and selectivity for Akt2 specifically are expected to further discussions in our evaluation of options for a licensing agreement.” COTI will be represented at Biotech Showcase by Dr. Wayne Danter, President and CEO and Mr. Michael Barr, Vice President of Business Development and Marketing.
About Critical Outcome Technologies Inc. (COTI) - www.criticaloutcome.com
COTI is formed around a unique computational platform technology called CHEMSAS®, which allows for accelerated identification and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. COTI is focused on preparing its lead anti-cancer compound, COTI-2, for an Investigational New Drug filing in the USA in 2011. In addition to COTI-2, the company has a significant preclinical pipeline targeting large market opportunities such as: adult acute leukemia and other cancers, multiple sclerosis, HIV integrase, and Alzheimer’s disease.
For further information, please visit the website at www.criticaloutcome.com or contact:
Vice President of Business Development and Marketing
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.